Browse > Article
http://dx.doi.org/10.3904/kjim.2015.30.2.133

Roadmap for elimination of gastric cancer in Korea  

Graham, David Y. (Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine)
Publication Information
The Korean journal of internal medicine / v.30, no.2, 2015 , pp. 133-139 More about this Journal
Abstract
Most gastric cancers are caused by infection with the common human bacterial pathogen, Helicobacter pylori. It is now accepted that gastric cancer can be prevented and virtually eliminated by H. pylori eradication and this knowledge was responsible for country-wide H. pylori eradication combined with secondary cancer prevention for those with residual risk that was introduced in Japan in 2013. Korea is a high H. pylori prevalence and high gastric cancer incidence country and a good candidate for a gastric cancer elimination program. The presence of an H. pylori infection is now considered as an indication for treatment of the infection. However, antimicrobial drug resistance is common among H. pylori in Korea making effective therapy problematic. Country-wide studies of the local and regional antimicrobial resistance patterns are needed to choose the most appropriate therapies. H. pylori and gastric cancer eradication can be both efficient and cost effective making it possible and practical to make Korea H. pylori and gastric cancer free. There is no reason to delay.
Keywords
Stomach neoplasms; Helicobacter pylori; Eradication therapy; Cancer prevention; Primary prevention;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Graham DY. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World J Gastroenterol 2014;20:5191-5204.   DOI   ScienceOn
2 Comfort MW. Gastric acidity before and after development of gastric cancer: its etiologic, diagnostic and prognostic significance. Ann Intern Med 1951;34:1331-1348.   DOI   ScienceOn
3 Graham DY, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. J Gastroenterol 2010;45:1-8.   DOI
4 Cheli R, Perasso A, Giacosa A. Gastritis: A Clinical Review. Berlin: Springer-Verlag, 1987.
5 Correa P. A human model of gastric carcinogenesis. Cancer Res 1988;48:3554-3560.
6 Shiotani A, Cen P, Graham DY. Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol 2013;23(6 Pt B):492-501.   DOI   ScienceOn
7 Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;1:1273-1275.
8 International Agency for Research on Cancer, ed. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 61, Schistosomes, Liver Flukes and Helicobacter pylori. Lyon: International Agency for Research on Cancer, 1994.
9 International Agency for Research on Cancer, ed. IARC Working Group Reports. Vol. 8, Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. Lyon: International Agency for Research on Cancer, 2014.
10 Asaka M, Kato M, Sakamoto N. Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan. J Gastroenterol 2014;49:1-8.   DOI   ScienceOn
11 Asaka M. A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer 2013;132:1272-1276.   DOI   ScienceOn
12 Graham DY, Shiotani A. The time to eradicate gastric cancer is now. Gut 2005;54:735-738.   DOI   ScienceOn
13 Bracken MB. Risk, Chance, and Causation: Investigating the Origins and Treatment of Disease. New Haven: Yale University Press, 2013.
14 Hanada K, Uchida T, Tsukamoto Y, et al. Helicobacter pylori infection introduces DNA double-strand breaks in host cells. Infect Immun 2014;82:4182-4189.   DOI   ScienceOn
15 Wang C, Weber A, Graham DY. Age, period, and cohort effects on gastric cancer mortality. Dig Dis Sci 2015;60:514-523.   DOI   ScienceOn
16 Lim SH, Kwon JW, Kim N, et al. Prevalence and risk factors of Helicobacter pylori infection in Korea: nationwide multicenter study over 13 years. BMC Gastroenterol 2013;13:104.   DOI   ScienceOn
17 Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008;40:650-658.   DOI   ScienceOn
18 Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138-143.   DOI   ScienceOn
19 Shin DW, Cho J, Kim SH, et al. Preferences for the "screen and treat" strategy of Helicobacter pylori to prevent gastric cancer in healthy Korean populations. Helicobacter 2013;18:262-269.   DOI   ScienceOn
20 Park JM, Hahm KB. The Korean perspective of Helicobacter pylori infection: lessons from the Japanese government's policy to prevent gastric cancer. Dig Dis 2014;32:290-294.   DOI   ScienceOn
21 Chung JW, Lee GH, Han JH, et al. The trends of oneweek first-line and second-line eradication therapy for Helicobacter pylori infection in Korea. Hepatogastroenterology 2011;58:246-250.
22 Yoon JH, Baik GH, Sohn KM, et al. Trends in the eradication rates of Helicobacter pylori infection for eleven years. World J Gastroenterol 2012;18:6628-6634.   DOI   ScienceOn
23 Jung YS, Lee SH, Park CS, et al. Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years. Korean J Gastroenterol 2014;63:82-89.   DOI   ScienceOn
24 Jeon HK, Kim GH. Does standard triple therapy still have a role in first-line Helicobacter pylori eradication in Korea? J Korean Med Sci 2014;29:619-620.   DOI   ScienceOn
25 Gong EJ, Yun SC, Jung HY, et al. Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change? J Korean Med Sci 2014;29:704-713.   DOI   ScienceOn
26 Hanada K, Graham DY. Helicobacter pylori and the molecular pathogenesis of intestinal-type gastric carcinoma. Expert Rev Anticancer Ther 2014;14:947-954.   DOI   ScienceOn
27 Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014;12:177.e3-186.e3.   DOI   ScienceOn
28 Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am 2010;39:465-480.   DOI   ScienceOn
29 Lee SY. Future candidates for indications of Helicobacter pylori eradication: do the indications need to be revised? J Gastroenterol Hepatol 2012;27:200-211.   DOI   ScienceOn
30 International Agency for Research on Cancer, ed. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 100B, Biologic Agents: A Review of Human Carcinogens. Lyon: International Agency for Research on Cancer, 2012:385-435.
31 Wu JY, Liou JM, Graham DY. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol 2014;8:21-28.   DOI   ScienceOn
32 The Research Group for Population-based Cancer Registration in Japan. Cancer incidence and incidence rates in Japan in 1986: estimates based on data from nine population-based cancer registries. Jpn J Clin Oncol 1991;21:318-323.   DOI